Printer Friendly

Champions Sports, Inc. Changes Name to Champions Biotechnology, Inc.

ARLINGTON, Va., Jan. 22 /PRNewswire-FirstCall/ -- Champions Sports, Inc. (BULLETIN BOARD: CSBR) , announced today the change of its name to Champions Biotechnology, Inc. The Company sold its Champions service mark and concept for sports themed restaurants to Marriott International, Inc. in 1997 and has since been seeking a new business direction. The change of name is intended reflect the decision of the Company to focus on biotechnology as its new business approach.

Recently, Dr. David Sidransky and Dr. Manuel Hidalgo, both with established credentials in the field of biotechnology, have become major investors with the Company. The management and owners of the Company intend to use their expertise to build a biotechnology company and have decided to seek ventures in that field.

The change of name to Champions Biotechnology, Inc. has been filed with the State of Delaware.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. The Company generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors, which may include, but are not limited to, changes in general economic conditions, the ongoing threat of terrorism, ability to have access to financing sources on reasonable terms and other risks that are described in this document. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and the Company's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

CONTACT: James Martell of Champions Biotechnology, Inc. (703)-526-0400.

CONTACT: James Martell of Champions Biotechnology, Inc., +1-703-526-0400
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 2007
Words:346
Previous Article:AutoWay Toyota and LoJack Corporation Host 'Catch A Car Thief' Event.
Next Article:Brady Center Report Reveals 'Shady Dealings' by Licensed Gun Dealers That Supply Gunrunners: Two Georgia Dealers Among Those Cited.
Topics:


Related Articles
Annie Duke Wins World Series of Poker Tournament of Champions; First Woman to Pocket Multi-Million-Dollar Prize Puts a New Face on Traditionally...
Champions Biotechnology, Inc. Acquires Biomerk, Inc.
Dr. Manuel Hidalgo Appointed Director and Scientific Advisor of Champions Biotechnology, Inc.
Dr. David Sidransky Appointed Director of Champions Biotechnology, Inc.
Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share.
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs.
Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs.
Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate.
Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters